Zoom In IconArrows pointing outwardsRoThe direct-to-consumer health-care startup Ro launched a new free tool Tuesday to help patients determine whether their insurance covers a buzzy class of weight loss and diabetes drugs called GLP-1s. Most insurance plans cover GLP-1s when they are used to treat diabetes, so those patients can usually avoid the roughly $1,000 monthly price tag of the medications.

放大Iconrowns指向外部的Roth direct to consumer health care startup Ro周二推出了一個新的免費工具，幫助患者確定他們的保險是否涵蓋了一類熱門的減肥和糖尿病藥物GLP-1s。當(dāng)GLP-1用于治療糖尿病時，大多數(shù)保險計劃都涵蓋了GLP-1，因此這些患者通?？梢员苊饷吭麓蠹s1000美元的藥物價格。

But coverage of weight loss treatments is less widespread, and navigating the complex insurance landscape can be challenging for patients and time consuming for doctors who prescribe the medications. Some patients may be missing out on treatment because they simply don't know they have coverage. Ro said nearly half of the company's patients have some form of insurance coverage for a GLP-1, according to its customer data. Ro said it hopes its new tool can help patients understand their coverage options so they can decide how to pursue weight loss.

但減肥治療的覆蓋面不太廣，復(fù)雜的保險環(huán)境對患者來說是一個挑戰(zhàn)，對開處方的醫(yī)生來說也是一個耗時的過程。一些患者可能會錯過治療，因為他們根本不知道自己有覆蓋范圍。羅表示，根據(jù)其客戶數(shù)據(jù)，該公司近一半的患者都有某種形式的GLP-1保險。Ro表示，它希望它的新工具能夠幫助患者了解他們的覆蓋范圍選擇，以便他們可以決定如何減肥。

The digital health company may benefit too, as it could drive some patients to join the company's GLP-1 program.Demand for GLP-1s, including Novo Nordisk's weight loss treatment Wegovy and diabetes injection Ozempic, has outstripped supply over the last year in the U.S. Other drugmakers — and digital health companies like Ro — are scrambling to capitalize on the booming GLP-1 market, which analysts say could be worth more than $100 billion by the end of the decade. Patients in Ro's program can get prescribed a GLP-1, and the company also offers compounded versions of the medication when the branded versions are in short supply.

數(shù)字健康公司也可能受益，因為它可能會促使一些患者加入該公司的GLP-1計劃。去年，包括諾和諾德公司（Novo Nordisk）的減肥治療藥物Wegovy和糖尿病注射液Ozempic在內(nèi)的GLP-1的需求超過了美國的供應(yīng)。其他制藥商——以及像Ro這樣的數(shù)字健康公司——正爭先恐后地利用蓬勃發(fā)展的GLP-1市場，分析師表示，到本十年末，該市場的價值可能超過1000億美元。Ro計劃中的患者可以獲得GLP-1處方，當(dāng)品牌藥物短缺時，該公司還提供復(fù)合藥物。

Compounded GLP-1s are custom-made alternatives to brand drugs designed to meet a specific patient's needs. The program also allows patients to meet monthly with a doctor and access an educational curriculum f.

復(fù)合GLP-1是定制的替代品牌藥物，旨在滿足特定患者的需求。該計劃還允許患者每月與醫(yī)生會面，并獲得教育課程f。

相關(guān)知識

數(shù)字健康公司Ro推出GLP
康寶萊推出GLP
AI創(chuàng)新者NotCo推出GLP
Nemaura推出與GLP
Elevance推出體重管理計劃，包括GLP
Ypsomed和Sidekick Health推出了一項針對肥胖管理的協(xié)作數(shù)字健康解決方案
媲美司美格魯肽GLP
司美格魯肽與市售GLP
通化東寶：加速推進(jìn)GLP
司美臉來襲，GLP

網(wǎng)址: 數(shù)字健康公司Ro推出GLP http://m.u1s5d6.cn/newsview1560830.html